Your browser doesn't support javascript.
loading
Neuroprotective Effects of Tryptanthrin-6-Oxime in a Rat Model of Transient Focal Cerebral Ischemia.
Plotnikov, Mark B; Chernysheva, Galina A; Smol'yakova, Vera I; Aliev, Oleg I; Anishchenko, Anna M; Ulyakhina, Olga A; Trofimova, Eugene S; Ligacheva, Anastasia A; Anfinogenova, Nina D; Osipenko, Anton N; Kovrizhina, Anastasia R; Khlebnikov, Andrei I; Schepetkin, Igor A; Drozd, Anastasia G; Plotnikov, Evgenii V; Atochin, Dmitriy N; Quinn, Mark T.
Afiliação
  • Plotnikov MB; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Chernysheva GA; Faculty of Radiophysics, National Research Tomsk State University, Tomsk 634050, Russia.
  • Smol'yakova VI; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Aliev OI; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Anishchenko AM; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Ulyakhina OA; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Trofimova ES; Department of Pharmacology, Siberian State Medical University, Tomsk 634050, Russia.
  • Ligacheva AA; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Anfinogenova ND; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Osipenko AN; Department of Pharmacology, Siberian State Medical University, Tomsk 634050, Russia.
  • Kovrizhina AR; Department of Pharmacology, Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634028, Russia.
  • Khlebnikov AI; Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634012, Russia.
  • Schepetkin IA; Department of Pharmacology, Siberian State Medical University, Tomsk 634050, Russia.
  • Drozd AG; Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia.
  • Plotnikov EV; Kizhner Research Center, Tomsk Polytechnic University, Tomsk 634050, Russia.
  • Atochin DN; Department of Microbiology and Cell Biology, Montana State University, Bozeman, MT 59717, USA.
  • Quinn MT; Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
Pharmaceuticals (Basel) ; 16(8)2023 Jul 25.
Article em En | MEDLINE | ID: mdl-37630972
The activation of c-Jun N-terminal kinase (JNK) plays an important role in stroke outcomes. Tryptanthrin-6-oxime (TRYP-Ox) is reported to have high affinity for JNK and anti-inflammatory activity and may be of interest as a promising neuroprotective agent. The aim of this study was to investigate the neuroprotective effects of TRYP-Ox in a rat model of transient focal cerebral ischemia (FCI), which involved intraluminal occlusion of the left middle cerebral artery (MCA) for 1 h. Animals in the experimental group were administered intraperitoneal injections of TRYP-Ox 30 min before reperfusion and 23 and 47 h after FCI. Neurological status was assessed 4, 24, and 48 h following FCI onset. Treatment with 5 and 10 mg/kg of TRYP-Ox decreased mean scores of neurological deficits by 35-49 and 46-67% at 24 and 48 h, respectively. At these doses, TRYP-Ox decreased the infarction size by 28-31% at 48 h after FCI. TRYP-Ox (10 mg/kg) reduced the content of interleukin (IL) 1ß and tumor necrosis factor (TNF) in the ischemic core area of the MCA region by 33% and 38%, respectively, and attenuated cerebral edema by 11% in the left hemisphere, which was affected by infarction, and by 6% in the right, contralateral hemisphere 24 h after FCI. TRYP-Ox reduced c-Jun phosphorylation in the MCA pool at 1 h after reperfusion. TRYP-Ox was predicted to have high blood-brain barrier permeability using various calculated descriptors and binary classification trees. Indeed, reactive oxidant production was significantly lower in the brain homogenates from rats treated with TRYP-Ox versus that in control animals. Our data suggest that the neuroprotective activity of TRYP-Ox may be due to the ability of this compound to inhibit JNK and exhibit anti-inflammatory and antioxidant activity. Thus, TRYP-Ox may be considered a promising neuroprotective agent that potentially could be used for the development of new treatment strategies in cerebral ischemia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Suíça

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Federação Russa País de publicação: Suíça